JPRN-UMIN000027382
Completed
Phase 2
Phase II randomized clinical trial to investigate efficacy of zoledronic acid for the patients with metastatic or advanced breast cancer - Randomized clinical trial to investigate efficacy of zoledronic acid for the patients with metastatic or advanced breast cancer
Kyushu Breast Cancer Study Group (KBC-SG)0 sites90 target enrollmentMay 19, 2017
ConditionsMetastatic breast cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Metastatic breast cancer
- Sponsor
- Kyushu Breast Cancer Study Group (KBC-SG)
- Enrollment
- 90
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) There is any infection or complication of teeth 2\) History of allergy by zoledronic acud 3\) Patients with osteoporosis who needs therapy by bisphosphonates
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A randomized phase 2 trial which investigate the most effective administration method of antithrombin (AT) products in patients with disseminated intravascular coagulation (DIC) associated with sepsis during treatment for advanced pancreatic and biliary cancer.advanced hepatobiliary and pancreatic cancer patientsJPRN-UMIN000015105Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Medical Oncology40
Suspended
Phase 2
A phase II randomized clinical trial to determine the effectiveness of goreisan and saireito for lower limb lymphedema in women treated for gynecologic cancerower Limb LymphedemaLymphedemaD008209JPRN-jRCT1041190019Kajiyama Hiroaki40
Completed
Phase 2
Efficacy of a new COVID-19 treatmentPACTR202006899597082Malagasy government60
Active, not recruiting
Phase 1
Evaluating the effect of Loratadine associated with Rapamune in Lymphagioleiomyomatosis (LAM).EFFECT OF LORATADINE ON LYMPHANGIOLEIOMYOMATOSISMedDRA version: 21.0Level: PTClassification code 10049459Term: LymphangioleiomyomatosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2020-000702-29-ESIDIBELL (Institut d’Investigació Biomédica de Bellvitge)62
Completed
Not Applicable
Phase II randomized clinical trial for the purpose of examining the protective efficacy of the non-alcoholic fatty liver development by pancrelipase preparation being given for pancreatic cancer patients who underwent pancreaticoduodenectomy or total pancreatectomy.To assume the decreased rate of post-operative non-alcoholic fatty liver incidence in pancreatic cancer patients with the prophylactic administration of the pancrelipase preparation.JPRN-UMIN000019817Department of Surgery, Kansai Medical University80